Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jul;65(1):71-75.
doi: 10.3164/jcbn.19-30. Epub 2019 Jun 11.

Differences in Helicobacter pylori and CagA Antibody Changes After Eradication Between Subjects Developing and Not Developing Gastric Cancer

Affiliations
Free PMC article

Differences in Helicobacter pylori and CagA Antibody Changes After Eradication Between Subjects Developing and Not Developing Gastric Cancer

Masaaki Kodama et al. J Clin Biochem Nutr. .
Free PMC article

Abstract

We evaluated serological Helicobacter pylori and cytotoxin-associated gene A (CagA) antibodies and endoscopic atrophy after eradication to identify factors predicting post-eradication gastric cancer development. Thirty-five patients with successful eradiation were divided into the post-eradication gastric cancer (13 cases) and non-gastric cancer (22 cases) groups. Serum Helicobacter pylori and CagA antibody titers and endoscopic atrophy before and six years after eradication were examined. Median Helicobacter pylori antibody titers had decreased significantly from baseline at 0.5-2 years after eradication in both groups (gastric cancer group, from 39.0 to 11.0 U/ml, p = 0.011; non-gastric cancer group, from 29.6 to 4.97 U/ml, p<0.001), but were significantly higher in the gastric cancer than in the non-gastric cancer group (p = 0.029). Median serum CagA antibody titers had also decreased significantly at 0.5-2 years after eradication (gastric cancer group, from 6.35 to 3.23 U/ml, p = 0.028; non-gastric cancer group, from 9.88 to 1.21 U/ml, p = 0.0045). Serum CagA in each group showed no significance. Endoscopic atrophy improved significantly after eradication in the non-gastric cancer, but not the gastric cancer, group (p = 0.0007). In conclusion, changes in Helicobacter pylori and CagA antibody titers and endoscopic atrophy after eradication might be useful as predictive factors for post-eradication gastric cancer.

Keywords: CagA antibody; Helicobacter pylori; Helicobacter pylori antibody; eradication; gastric cancer.

Conflict of interest statement

The authors report no conflict of interest. The authors alone are responsible for the content and writing of the paper.

Figures

Fig. 1
Fig. 1
Serum Helicobacter pylori antibody titers in the gastric cancer and non–gastric cancer groups. Data are medians ± SDs. aWilcoxon signed-ranks test, bStudent’s t test. GC, gastric cancer.
Fig. 2
Fig. 2
Serum CagA antibody titers in the gastric cancer and non-gastric cancer groups. Data are medians ± SDs. aWilcoxon signed-ranks test, bStudent’s t test. GC, gastric cancer.
Fig. 3
Fig. 3
Endoscopic atrophy score before and after Helicobacter pylori eradication in the gastric cancer and non-gastric cancer groups. Data are medians with interquartile ranges. aWilcoxon signed-ranks test, bStudent’s t test. GC, gastric cancer.

Similar articles

See all similar articles

References

    1. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784–789. - PubMed
    1. Suerbaum S, Michetti P. Helicobacter pylori infection. N Engl J Med 2002; 347: 1175–1186. - PubMed
    1. Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial. Lancet 2008; 372: 392–397. - PubMed
    1. Take S, Mizuno M, Ishiki K, et al. Seventeen-year effects of eradicating Helicobacter pylori on the prevention of gastric cancer in patients with peptic ulcer; a prospective cohort study. J Gastroenterol 2015; 50: 638–644. - PubMed
    1. Ford AC, Forman D, Hunt RH, Yuan Y, Moayyedi P. Helicobacter pylori eradication therapy to prevent gastric cancer in healthy asymptomatic infected individuals: systematic review and meta-analysis of randomised controlled trials. BMJ 2014; 348: g3174. - PMC - PubMed
Feedback